Drug Target Review2026-05-29T12:00:00
Researchers have identified metabolic vulnerabilities in Fibrolamellar cancer, a rare liver malignancy affecting adolescents and young adults, using functional profiling and mass spectrometry. The findings suggest chemotherapy-resistant tumours may be susceptible to metabolism-targeted therapies.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-09-24T06:30:00Z
Contributor Dr Dan Benjamin, Drug Target Review
2024-05-07T13:11:19
Sponsored by BellBrook Labs
2026-06-15T07:00:00
Contributor Professor Dipak Ramji, Drug Target Review
2025-05-08T09:00:00
Contributor Ning Ren
2023-01-04T16:08:55
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2026-07-23T06:20:00
Contributor Laura Lotfi, Drug Target Review
Site powered by Webvision Cloud